血管内皮生长因子受体2(VEGFR2)活性蛋白

Active Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)

CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1

  • 血管内皮生长因子受体2(VEGFR2)活性蛋白产品包装(模拟)
  • 血管内皮生长因子受体2(VEGFR2)活性蛋白产品包装(模拟)
  • 血管内皮生长因子受体2(VEGFR2)活性蛋白Figure. Gene Sequencing (Extract)
  • APB367Hu61.pngFigure. SDS-PAGE
  • Certificate通过ISO 9001、ISO 13485质量体系认证

活性实验

Figure. Cell proliferation of ECV-304 cells inhibit by VEGFR2.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) also known as kinase insert domain receptor acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. VEGFR2 functions as the primary mediator of vascular endothelial growth factor activation in endothelial cells. Regulation of VEGFR-2 expression appears critical in mitogenesis, differentiation, and angiogenesis. To test the effect on inhibit the VEGF-dependent proliferation of endothelium cells, ECV-304 cells were seeded into triplicate wells of 96-well plates at a density of 5,000 cells/well and allowed to attach, replaced with serum-free overnight, then the medium was replaced with 2% serum standard DMEM including 1μg/mL Vascular Endothelial Growth Factor C (VEGFC) and various concentrations of recombinant human VEGFR2. After incubated for 96h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37℃. Proliferation of ECV-304 cells after incubation with VEGFR2 for 96h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinant VEGFR2 for 96h. The result was shown in Figure 2. It was obvious that VEGFR2 significantly inhibit cell viability of ECV-304.
(A) ECV-304 cells cultured in DMEM, stimulated with 10ng/mL VEGFR2 for 96h;
(B) Unstimulated ECV-304 cells cultured in DMEM for 96h.

Figure. VEGFR2 inhibit VEGF-dependent proliferation of ECV-304 cells.

用法

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

储存

避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

相关产品

编号适用物种:Homo sapiens (Human,人)应用(仅供研究使用,不用于临床诊断!)
APB367Hu61血管内皮生长因子受体2(VEGFR2)活性蛋白Cell culture; Activity Assays.
EPB367Hu61血管内皮生长因子受体2(VEGFR2)真核蛋白Positive Control; Immunogen; SDS-PAGE; WB.
APB367Hu01血管内皮生长因子受体2(VEGFR2)活性蛋白Cell culture; Activity Assays.
RPB367Hu01血管内皮生长因子受体2(VEGFR2)重组蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAB367Hu01血管内皮生长因子受体2(VEGFR2)多克隆抗体WB; IHC; ICC; IP.
LAB367Hu81血管内皮生长因子受体2(VEGFR2)多克隆抗体(异硫氰酸荧光素标记)WB; IHC; ICC; IF.
LAB367Hu71血管内皮生长因子受体2(VEGFR2)多克隆抗体(生物素标记)WB; IHC; ICC.
FAB367Hu51抗血管内皮生长因子受体2(VEGFR2)多克隆抗体(别藻蓝蛋白标记)FCM
MAB367Hu23血管内皮生长因子受体2(VEGFR2)单克隆抗体WB; IHC; ICC; IP.
MAB367Hu26血管内皮生长因子受体2(VEGFR2)单克隆抗体WB; IHC; ICC; IP.
RAB367Hu21血管内皮生长因子受体2(VEGFR2)重组抗体WB; IF; ICC; IHC; IP; FCM.
MAB367Hu22血管内皮生长因子受体2(VEGFR2)单克隆抗体WB; IHC; ICC; IP.
MAB367Hu24血管内皮生长因子受体2(VEGFR2)单克隆抗体WB; IHC; ICC; IP.
MAB367Hu21血管内皮生长因子受体2(VEGFR2)单克隆抗体WB; IHC; ICC; IP.
FAB367Hu32抗血管内皮生长因子受体2(VEGFR2)单克隆抗体(别藻蓝蛋白/花青染料cy7标记)FCM
FAB367Hu82抗血管内皮生长因子受体2(VEGFR2)单克隆抗体(异硫氰酸荧光素标记)Flow cytometry.
HEB367Hu血管内皮生长因子受体2(VEGFR2)检测试剂盒(酶联免疫吸附试验法,高敏型)Enzyme-linked immunosorbent assay for Antigen Detection.
SEB367Hu血管内皮生长因子受体2(VEGFR2)检测试剂盒(酶联免疫吸附试验法)Enzyme-linked immunosorbent assay for Antigen Detection.
LMB367Hu血管内皮生长因子受体2(VEGFR2)等多因子检测试剂盒(流式荧光发光法)FLIA Kit for Antigen Detection.
KSB367Hu01血管内皮生长因子受体2(VEGFR2)检测试剂盒DIY材料(酶联免疫吸附试验法)自己动手制作ELISA试剂盒的主要材料

参考文献

杂志参考文献
APMISPeritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway[PubMed: 23398358]
Acta BiomaterAntioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study[PubMed: 26689470]
Acta BiomaterialiaAntioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study[Pubmed:26689470]
Journal of Cellular PhysiologyA Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells.[pubmed:27925188]
Regenerative BiomaterialsThe directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic[10.1093/rb/rbx028]
International Journal of Immunopathology and PharmacologyVEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these …[Pubmed:29985074]
JOURNAL OF DERMATOLOGICAL TREATMENTEffect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris[Pubmed: 32043381]
Journal of Genetic Engineering and BiotechnologyEncapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells[33523322]
Mol Cell BiochemIntuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy[34324118]
BMC NephrolEffect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneys[Pubmed:35643467]